Aib substitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
the tenor of the time had generally turned against... outlandishness and people had mostly returned to looking more like people over the last millennium... (previously) as the fashions of the intervening times had ordained – people... had resembled birds, fish, dirigible balloons, snakes, small clouds of cohesive smoke and animated bushes. Some Culture citizens opt to leave the constraints of a human or even humanoid body altogether, opting to take on the appearance of one of the myriad other galactic sentients (perhaps in order to live with them) or even non-sentient objects as commented upon in Matter (though this process can be irreversible if the desired form is too removed from the structure of the human brain). Certain eccentrics have chosen to become drones or even Minds themselves, though this is considered rude and possibly even insulting by most humans and AIs alike. While the Culture is generally pan-humanoid (and tends to call itself "human"), various other species and individuals of other species have become part of the Culture. As all Culture citizens are of perfect genetic health, the very rare cases of a Culture citizen showing any physical deformity are almost certain to be a sort of fashion statement of somewhat dubious taste.
Surveillance studies from 2005 and later show the estimated global incidence is 1–2 cases per million population per year. Sporadic CJD (sCJD) incidence increased from the years 1990–2018 in the UK. Probable or definite sCJD deaths also increased from the years 1996–2018 in twelve additional countries. CJD incidence is greatest in those over the age of 55 years old, with an average age of 67 years old. The intensity of CJD surveillance increases the number of reported cases, often in countries where CJD epidemics have occurred in the past and where surveillance resources are greatest. An increase in surveillance and reporting of CJD is most likely in response to BSE and vCJD. Possible factors contributing to an increase in CJD incidence are an aging population, population increase, clinician awareness, and more accurate diagnostic methods. Since CJD symptoms are similar to other neurological conditions, it is also possible that CJD is mistaken for stroke, acute nephropathy, general dementia, and hyperparathyroidism.
== Pharmacology == JDTic is a potent KOR antagonist, and is highly selective for KOR over μ- (MOR) and δ-opioid receptors (DOR), along with many non-opioid receptors. However, it shows modest affinity for the nociceptin receptor (NOP). In one study, JDTic showed little binding selectivity over the μ-opioid receptor, but it failed to block the effects of the selective μ-opioid receptor agonist sufentanil across a wide range of doses in animals. It has a very long duration of action, with effects in animals seen for up to several weeks after administration of a single dose, although its binding to the KOR is not irreversible; its long duration of action is instead caused by activation of a c-Jun N-terminal kinase. Animal studies suggest that JDTic may produce antidepressant, anxiolytic, and anti-stress effects, as well as having possible application in the treatment of addiction to cocaine and morphine. JDTic shows robust activity in animal models of depression, anxiety, stress-induced cocaine relapse, and nicotine withdrawal.
Illegal efforts to weaponize methaqualone have occurred. During the 1980s, the apartheid regime in South Africa ordered the covert manufacture of a large amount of methaqualone at the front company Delta G Scientific Company, as part of a secret chemical weapons program known as Project Coast. Methaqualone was given the codename MosRefCat (Mossgas Refinery Catalyst). Details of this activity came to light during the 1998 hearings of the post-apartheid Truth and Reconciliation Commission.
Sources: en.wikipedia.org
In January 2021, Taco Bell announced the return of potatoes to the menu after a brief discontinuation in August 2020 in efforts to streamline processes in their restaurants in response to the COVID-19 pandemic. In addition to the potatoes, the company had announced plans to expand their vegetarian menu by introducing Beyond Meat as a plant-based vegetarian customization option. In April 2021, Taco Bell said that it would start reusing hot sauce packets in partnership with the recycling company TerraCycle, aiming to reduce the environmental pollution. In August 2021, Taco Bell announced the Crispy Chicken Sandwich Taco. On January 6, 2022, Taco Bell launched a digital taco subscription service called the Taco Lover's Pass through the company app. For the cost of $10, a customer can order one of seven different tacos each day for 30 consecutive days. On April 18, 2022, Taco Bell announced that Mexican Pizza would return to its menu on May 19, after its having previously been discontinued in November 2020. From July to August 2022, filmmaker Sam Reid ate nothing but Taco Bell for 30 days, testing the nutritional content of the food in a similar vein to Super Size Me. The stunt gained widespread national attention for both Sam and the fast food chain, including multiple news stations covering his diet and a mention by Jimmy Fallon on The Tonight Show. Reid published a documentary about the challenge on his YouTube channel in October the same year.
== Venom == The venom of the Wagler's pit viper contains four novel peptides (Waglerins 1-4). The Waglerins produce fatal respiratory paralysis of adult mice. An initial study indicated that micromolar concentrations of Waglerin 1 act both pre- and postsynaptically to inhibit transmission across rat neuromuscular junctions. However, Waglerin-1 is a more potent inhibitor of transmission across the mouse neuromuscular junction. A subsequent study demonstrated that Waglerin-1 inhibited the adult mouse endplate response to acetylcholine with an IC50 of 50 nanomolar. In striking contrast, transmission across neuromuscular junctions of neonatal or transgenic mice lacking the adult acetylcholine receptor was not altered by micromolar concentrations of Waglerin-1. Biochemical studies demonstrated that the exquisite selectivity of Waglerin-1 for the adult mouse acetylcholine receptor relies upon several amino acid residues unique to the epsilon subunit of the adult mouse acetylcholine receptor. Waglerin-1's selectivity for the epsilon-subunit containing acetylcholine receptor of adult mice is complemented by selectivity of small peptide toxins purified from the venom of Conus geographus and Conus pergrandis for the gamma-subunit containing acetylcholine receptor of neonatal skeletal muscle. The Waglerins and complementary conotoxins are useful tools to discover the contribution of acetylcholine receptor subunits to synaptogenesis. In addition, study of the Waglerins and related toxic peptides may lead to the discovery of novel molecular targets for drug development.
This time, the internet amplified the proposition and spawned a hundred frauds and scams. However, their adoption of the "HGH" term has provided an easy way to distinguish the hype from the evidence. In 2003, growth hormone hit the news again, when the US FDA granted Eli Lilly approval to market Humatrope for the treatment of idiopathic short stature. The indication was controversial for several reasons, the primary one being the difficulty in defining extreme shortness with normal test results as a disease rather than the extreme end of the normal height range Recombinant growth hormone available in the U.S. (and their manufacturers) include Nutropin (Genentech), Humatrope (Eli Lilly and Company), Genotropin (Pfizer), Norditropin (Novo Nordisk), Tev-Tropin (Teva) and Saizen (Merck Serono). The products are nearly identical in composition, efficacy, and cost, varying primarily in the formulations and delivery devices. Somapacitan-beco (Sogroya) is the first once-per week subcutaneous human growth hormone (hGH) therapy that was approved in the United States. It was approved for medical use in the United States in August 2020.
Sources: en.wikipedia.org
TA-CD is a vaccine developed by the Xenova Group and designed to negate the effects of cocaine, making it suitable for use in treatment of addiction. It is created by combining norcocaine with inactivated cholera toxin.
== Awards and honours == 2007 Elected to the British Mass Spectrometry Society 2018 Elected Chair of the Management Advisory Panel for the EPSRC National Mass Spectrometry Facility 2022 Royal Society of Chemistry Analytical Division Theophilus Redwood Award
They also played "Rooster" with Comes with the Fall vocalist William DuVall and Ann Wilson. The band followed the concert with a short United States club tour named "Finish What We Started", several festival dates in Europe, and a brief tour in Japan. Duff McKagan again joined the band for the reunion tour, playing rhythm guitar on selected songs. During the tour, the band played a 5-minute video tribute to Staley during the changeover from the electric to acoustic set. To coincide with the band's reunion, Sony Music released the long-delayed third Alice in Chains compilation, The Essential Alice in Chains, a double album that includes 28 songs. Jerry Cantrell met William DuVall in Los Angeles in 2000 through a mutual acquaintance who introduced Cantrell to Comes with the Fall's first album. Cantrell started hanging out with the band and occasionally joined them onstage. Between 2001 and 2002, Comes with the Fall was both the opening act on Cantrell's tour for his second solo album, Degradation Trip, and also his backing band, with DuVall singing Staley's parts at the concerts. DuVall joined Alice in Chains as lead singer during the band's reunion concerts in 2006, and made his first public performance with the band at VH1's Decades Rock Live! concert. According to Cantrell, it only took one audition for DuVall to get the gig. For his first rehearsal with the band, DuVall sang "Love, Hate, Love".
==== Productivity loss ==== The estimated loss of human capital and productivity due to labor absenteeism in 2003 amounted to $366.2 billion. On the other hand, the loss of land productivity, which translates into a negative impact on administration, investment in physical and social capital, and the price of land in subsectors such as livestock and commercial agriculture is one of the consequences associated with the presence of an armed conflict. This cost is mainly assumed by farmers who experience the pressure of armed actions in their areas of operation. Within this context, the most serious consequences are related to the devaluation of the properties, the loss of productivity of the land (represented in the products that could potentially have been cultivated in these lands), and the difficulty in managing the efficient production of the lands. According to a study of National Planning, between 1999 and 2003 the estimated costs for the loss of productivity of land represented $140,443.5 million, equivalent to 1.28% of the GDP of the agricultural sector of 2003.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.